Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

A.M.M. Eggermont; S. Suciu; R. MacKie; W. Ruka; A. Testori; W. Kruit; C.J Punt; M. Delauney; F. Sales; G. Groenewegen; D.J. Ruiter; I. Jagiello; K. Stoitchkov; U. Keilholz; Group EORTC Melanoma; D. Lienard

doi:10.1016/S0140-6736

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Translated title of the contribution: Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

A.M.M. Eggermont
, S. Suciu
, R. MacKie
, W. Ruka
, A. Testori
, W. Kruit
, C.J Punt
, M. Delauney
, F. Sales
, G. Groenewegen
, D.J. Ruiter
, I. Jagiello
, K. Stoitchkov
, U. Keilholz
, Group EORTC Melanoma
, D. Lienard

Division Imaging & Oncology

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Original language	Undefined/Unknown
Pages (from-to)	1189-1196
Number of pages	8
Journal	The Lancet
Volume	366
DOIs	https://doi.org/10.1016/S0140-6736
Publication status	Published - 2005

Access to Document

10.1016/S0140-6736

Cite this

Eggermont, A. M. M., Suciu, S., MacKie, R., Ruka, W., Testori, A., Kruit, W., Punt, C. J., Delauney, M., Sales, F., Groenewegen, G., Ruiter, D. J., Jagiello, I., Stoitchkov, K., Keilholz, U., EORTC Melanoma, G., & Lienard, D. (2005). Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. The Lancet, 366, 1189-1196. https://doi.org/10.1016/S0140-6736

@article{508791adb73d44e0bd3b3824e950d20b,

title = "Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.",

author = "A.M.M. Eggermont and S. Suciu and R. MacKie and W. Ruka and A. Testori and W. Kruit and C.J Punt and M. Delauney and F. Sales and G. Groenewegen and D.J. Ruiter and I. Jagiello and K. Stoitchkov and U. Keilholz and \{EORTC Melanoma\}, Group and D. Lienard",

year = "2005",

doi = "10.1016/S0140-6736",

language = "Undefined/Unknown",

volume = "366",

pages = "1189--1196",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

}

Eggermont, AMM, Suciu, S, MacKie, R, Ruka, W, Testori, A, Kruit, W, Punt, CJ, Delauney, M, Sales, F, Groenewegen, G, Ruiter, DJ, Jagiello, I, Stoitchkov, K, Keilholz, U, EORTC Melanoma, G & Lienard, D 2005, 'Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.', The Lancet, vol. 366, pp. 1189-1196. https://doi.org/10.1016/S0140-6736

TY - JOUR

T1 - Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

AU - Eggermont, A.M.M.

AU - Suciu, S.

AU - MacKie, R.

AU - Ruka, W.

AU - Testori, A.

AU - Kruit, W.

AU - Punt, C.J

AU - Delauney, M.

AU - Sales, F.

AU - Groenewegen, G.

AU - Ruiter, D.J.

AU - Jagiello, I.

AU - Stoitchkov, K.

AU - Keilholz, U.

AU - EORTC Melanoma, Group

AU - Lienard, D.

PY - 2005

Y1 - 2005

U2 - 10.1016/S0140-6736

DO - 10.1016/S0140-6736

M3 - Article

SN - 0140-6736

VL - 366

SP - 1189

EP - 1196

JO - The Lancet

JF - The Lancet

ER -